TABLE 1.
Summary of virological and immunological status following various treatment regimens
| Group | Determination | No. positive at indicated wk p.i./no. tested
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 6 | 8 | 12 | 16 | 20 | 24 | 32 | 46 | ||
| A (mock-treated control; macaques 95012, 95023, 95032, 95041) | PBMC viremiaa | 0/4 | 4/4 | 3/4 | 3/4 | 3/4 | 3/4 | 4/4 | 4/4 | 3/4 | 3/4 | 4/4 | 3/4 |
| Plasma SIV RNA | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 3/4 | 4/4 | 3/3 | 3/3 | 3/4 | |
| PCR-viral DNAb | 3/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 3/4 | NDc | ND | 4/4 | |
| SIV antibodies | 0/4 | 0/4 | 0/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | |
| B (24-h postexposure, 28-day treatment; macaques 95025, 95044, 95054, M94312) | PBMC viremia | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| Plasma SIV RNA | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| PCR-viral DNA | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | |
| SIV antibodies | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 1/4 | |
| C (48-h postexposure, 28-day treatment; macaques 95026, 95035, 95043, 95059) | PBMC viremia | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 3/4 | 3/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 |
| Plasma SIV RNA | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 4/4 | 3/4 | 3/4 | 3/4 | 3/4 | 2/4 | 2/4 | |
| PCR-viral DNA | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 3/4 | 2/4 | 2/4 | 2/4 | ND | ND | 4/4 | |
| SIV antibodies | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 2/4 | 3/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | |
| D (72-h postexposure, 28-day treatment; macaques 95017, 95038, 95061, M95033) | PBMC viremia | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 2/4 | 2/4 | 2/4 | 2/4 | 2/4 | 2/4 | 2/4 |
| Plasma SIV RNA | 0/4 | 0/4 | 0/4 | 0/4 | 3/4 | 3/4 | 3/4 | 4/4 | 2/4 | 2/4 | 2/4 | 2/4 | |
| PCR-viral DNA | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 3/4 | 3/4 | 3/4 | 1/4 | ND | ND | 2/4 | |
| SIV antibodies | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | |
| E (24-h postexposure, 10-day treatment; macaques 95016, 95020, 95033, 95053) | PBMC viremia | 0/4 | 0/4 | 0/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 |
| Plasma SIV RNA | 0/4 | 0/4 | 1/4 | 1/4 | 2/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 | 1/4 | |
| PCR-viral DNA | 0/4 | 0/4 | 0/4 | 1/4 | 2/4 | 0/4 | 2/4 | 2/4 | 1/4 | ND | ND | 1/4 | |
| SIV antibodies | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 2/4 | 2/4 | 2/4 | 2/4 | 2/4 | 2/4 | 3/4 | |
| F (24-h postexposure, 3-day treatment; macaques 95015, 95030, M95018, 95052) | PBMC viremia | 0/4 | 0/4 | 1/4 | 3/4 | 1/4 | 1/4 | 2/4 | 2/4 | 2/4 | 2/4 | 2/4 | 2/4 |
| Plasma SIV RNA | 1/4 | 3/4 | 3/4 | 4/4 | 3/4 | 2/4 | 2/4 | 3/4 | 2/4 | 3/4 | 2/4 | 2/4 | |
| PCR-viral DNA | 0/4 | 0/4 | 1/4 | 4/4 | 3/4 | 4/4 | 4/4 | 3/4 | 2/4 | ND | ND | 2/4 | |
| SIV antibodies | 0/4 | 0/4 | 0/4 | 3/4 | 3/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | 4/4 | |
a
PBMC were titrated from 106 to 101 cells and then cocultured with C8166 cells to isolate infectious virus in this in vitro assay.
b
A nested PCR was used to detect SIV long terminal repeat DNA in 106 PBMCs.
c
ND, not determined.